Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting

May 30, 2019

Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights

May 13, 2019

Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock

April 24, 2019

Gritstone Oncology Announces Proposed Public Offering of Common Stock

April 22, 2019

Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback

April 22, 2019

Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board

April 4, 2019

Gritstone Oncology to Present at Needham Healthcare Conference

April 3, 2019

Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods

April 2, 2019

Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

March 28, 2019

Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001

March 21, 2019

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Next page
Last page

© 2021 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top